Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a multinational, non-interventional, cross-sectional survey conducted among HCPs based in the EU/EEA who prescribe Piqray. The survey assessed the knowledge of HCPs prescribing Piqray in relation to the management of hyperglycemia in patients treated with Piqray.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Piqray Prescriber's/HCP receiving the guide for hyperglycemia | HCPs prescribing Piqray in the EU/EEA provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Piqray Prescriber's/HCP guide for hyperglycemia | Other | oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA were provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aimed to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia. |
| Measure | Description | Time Frame |
|---|---|---|
| assess HCPs' knowledge and understanding of the key information included in the Piqray Prescriber's/HCP Guide for hyperglycemia | The primary endpoint was a composite endpoint based on the percentages of HCPs with correct responses to all questions included in the composite regarding the below information:
| Throughout study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Assess HCPs' reported levels of receipt, and reading, of the Piqray Prescriber's/HCP Guide for hyperglycemia | Assessed as the percentages of HCPs who report receipt and reading of the same (survey questions 1, 2). | Throughout study completion, an average of 1 year |
| Assess HCPs' knowledge levels for each survey question regarding knowledge of, and management of, hyperglycemia |
Not provided
Inclusion Criteria:
Exclusion Criteria:
HCPs who are direct employees of Novartis, the EMA (or any other regulatory bodies), or ICON.
Not provided
Not provided
Oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | Basel | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Assessed as the percentages of HCPs with correct responses to each question (individual responses to survey questions 4-15). |
| Throughout study completion, an average of 1 year |
| Assess the primary source from which HCPs learned about the messages included in the Piqray Prescriber's/HCP Guide for hyperglycemia | Assessed as the percentages of HCPs who report using each of the possible sources as the primary source they used (survey question 3). | Throughout study completion, an average of 1 year |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided